|
|
| |
ASCO Research Issues
|
ASCO is engaged in a number of initiatives and activities related to issues of importance to the conduct of cancer research. These issues include: (1) central review of clinical trials, (2) clinical trial endpoints, (3) embryonic stem cell research, (4) federal research funding, (5) patient-reported outcomes, and (6) quality clinical trial site project.
|
 |
|
Central Review of Clinical Trials:
ASCO supports centralized review of multi-center clinical trials to improve the consistency and efficiency of clinical trial review.
|
|
|
FDA Project on Cancer Drug Approval Endpoints:
ASCO organizes, along with the Food and Drug Administration (FDA), National Cancer Institute (NCI), and other professional societies, workshops to evaluate potential endpoints for cancer drug approval.
|
|
|
Embryonic Stem Cell Research Potential for Impacting Cancer:
ASCO supports increased opportunities for federally funded embryonic stem cell research.
|
|
|
Federal Research Funding:
This link provides information on the status of federal funding for the National Institutes of Health and National Cancer Institute.
|
|
|
Patient Reported Outcomes:
ASCO comments to the Food and Drug Administration (FDA) regarding its draft guidance entitled "Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims."
|
|
|
Quality Clinical Trial Site Project:
ASCO is in the process of creating a definition of a quality clinical trial site to provide a standard that sites can refer to when assessing their resources to conduct clinical trials.
|
|
|
|
|
|
|
|
|
|
